Ikarian Capital’s Solid Biosciences SLDB Stock Holding History

Ikarian Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-424,000	Closed	-$2.39M	–	206
2025 Q4	$2.39M	Sell	424,000 -44,000	-9%	-$238K	0.19%	95
2025 Q3	$2.89M	Buy	+468,000	New	+$2.74M	0.29%	83
2025 Q1	–	Sell	-300,000	Closed	-$1.2M	–	211
2024 Q4	$1.2M	Hold	300,000	–	–	0.16%	99
2024 Q3	$2.09M	Buy	+300,000	New	+$2.43M	0.29%	73
2020 Q2	–	Sell	-29,987	Closed	-$1.07M	–	207
2020 Q1	$1.07M	Buy	29,987 +9,614	+47%	+$476K	0.08%	120
2019 Q4	$1.36M	Buy	+20,373	New	+$2.25M	0.22%	72

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ikarian Capital's SLDB Position: Q1 2026 in Review

Ikarian Capital increased its Solid Biosciences (SLDB) stake by 65% in Q1 2026, buying an estimated $668K and bringing the position to 264,409 shares worth $1.9M. The position accounts for 0.15% of the portfolio, ranked #100.

Ikarian Capital first reported a position in SLDB in Q1 2020 and has held it in 13 quarters since. The position peaked at $5.97M in Q4 2020. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

Ikarian Capital held 264,409 shares of Solid Biosciences worth $1.9M as of Q1 2026.
Ikarian Capital bought 104,000 Solid Biosciences shares in Q1 2026, an estimated $668K.
Solid Biosciences made up 0.15% of Ikarian Capital's portfolio in Q1 2026, its #100 holding.
Ikarian Capital first reported a position in Solid Biosciences in Q1 2020 and has held it in 13 quarters since.
Ikarian Capital's Solid Biosciences position peaked at $5.97M in Q4 2020.
150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.